Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.
Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.4%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference2%
- Check21 days agoChange DetectedDifference0.4%
- Check28 days agoChange DetectedSeveral links related to chronic lymphocytic leukemia, lymphoma, and other rare diseases have been removed, indicating a potential shift in focus or resource availability on the website.SummaryDifference4%
- Check36 days agoChange DetectedNew resources related to leukemia, lymphoma, and chronic graft-versus-host disease have been added, including links to MedlinePlus, Rare Diseases, and DailyMed, which may be of particular interest to those seeking information on these conditions.SummaryDifference0.9%
- Check43 days agoChange DetectedThe website has been updated to version v2.12.2, adding new features for downloading data in various formats and allowing users to select specific fields for export.SummaryDifference4%
Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.